TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15778268
Drug: Neostigmine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.04 mg kg(‐1) and glycopyrrolate 0.01 mg kg(‐1)
Study: 12501883
Drug: Oral gemifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gemifloxacin 320 mg once daily (7-14 days)
Study: 12501883
Drug: IV ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ceftriaxone 2 g once daily (1-7 days) followed by oral cefuroxime 500 mg twice daily (1-13 days)
Study: 10362176
Drug: Birth weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth weight of at least 4000 g
Study: 2183645
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy (MPPT) - 1 g intravenously
Study: 29143428
Drug: Alfacalcidol 0.5
Normalized name: alfacalcidol 0.5 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 0.5 μg/day + Calcium 500 mg/day
Study: 29143428
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Calcium 500 mg/day
Study: 16911730
Drug: Pre-treatment attentional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment attentional bias
Study: 10588819
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (0.3 mg)
Study: 8738728
Drug: Isosorbide‐5‐mononitrate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (40 mg, orally; n = 12)
Study: 1820892
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 2 mg idaverine
Study: 1820892
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 1 mg idaverine
Study: 1820892
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 2 mg idaverine
Study: 1820892
Drug: Idaverine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idaverine (all doses)
Study: 6357018
Drug: Intermittent positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent positive pressure breathing (IPPB) therapy
Study: 6357018
Drug: Compressor nebulizer
Normalized name: Compressor Nebulizer NE-C25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compressor nebulizer therapy
Study: 27157843
Drug: Topical bimatoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bimatoprost ocular insert
Study: 27157843
Drug: Timolol (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (0.5% solution) eye drops
Study: 23808510
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (lignocaine)
Study: 14967869
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (CHO) 1.0 g x kg body mass(-1)
Study: 11069375
Drug: Adjuvant mitozantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant mitozantrone chemotherapy
Study: 8686962
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg 5‐ISMN once daily for one week followed by 60 mg 5‐ISMN once daily for one week
Study: 8686962
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg 5‐ISMN once daily for two weeks
Study: 8686962
Drug: Starting on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting on a low dosage
Study: 31200819
Drug: Chemotherapy (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (first line)
Study: 22652402
Drug: ASO3-adjuvanted H1N1pdm09
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASO3-adjuvanted H1N1pdm09 vaccine (Arepanrix, GSK) with TIV (Vaxigrip, Sanofi Pasteur) given concurrently
Study: 22652402
Drug: ASO3-adjuvanted H1N1pdm09
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASO3-adjuvanted H1N1pdm09 vaccine (Arepanrix, GSK) with TIV (Vaxigrip, Sanofi Pasteur) given sequentially (21 days later)
Study: 22652402
Drug: H1N1pdm09 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1N1pdm09 vaccine alone
Study: 18586189
Drug: Hyaluronidase injection
Normalized name: hyaluronidase Injection
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase injection (n = 71)
Study: 18586189
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection (control group, n = 68)
Study: 11906779
Drug: Separate injection
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injection vaccination (DTPw-HB and Hib)
Study: 10422951
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg for induction followed by propofol 75‐150 microg x kg(‐1) x min(‐1) for maintenance
Study: 10422951
Drug: Sevoflurane in
Normalized name: sevoflurane Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane in combination with N2O 67% in oxygen for induction and maintenance
Study: 11198784
Drug: Fibernat (dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibernat (dietary fiber preparation)
Study: 9107166
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg sublingual nitroglycerin administration
Study: 8473716
Drug: Nefazodone 200
Normalized name: NEFAZODONE 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 200 mg/day
Study: 8473716
Drug: Nefazodone 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 400 mg/day
Study: 8473716
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active compounds (Nefazodone and Imipramine)
Study: 8473716
Drug: Imipramine 150
Normalized name: imipramine pamoate 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 150 mg/day with alcohol
Study: 8473716
Drug: Nefazodone 200
Normalized name: NEFAZODONE 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 200 mg/day with alcohol
Study: 28938434
Drug: Insulin clamp
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin clamp studies
Study: 31911348
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of the opioid receptor antagonist naltrexone
Study: 26115878
Drug: Thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic plus exercise training
Study: 26115878
Drug: AT1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT1 receptor antagonist plus exercise training
Study: 21744082
Drug: L-BLP25 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-BLP25 plus BSC (stage IIIB loco-regional subgroup)
Study: 9227540
Drug: 10 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml/kg body weight of 0.5 M racemic sodium lactate
Study: 8435738
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor training programme (5 sessions, weekly, supervised by physiotherapists)
Study: 2956873
Drug: Enoximone 50
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 50 mg, 100 mg, or 150 mg, given 3 times daily for 4 weeks
Study: 2956873
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given 3 times daily for 4 weeks
Study: 2956873
Drug: Enoximone 50
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 50 mg and 100 mg, given 3 times daily
Study: 2956873
Drug: Enoximone 150
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 150 mg, given 3 times daily
Study: 2956873
Drug: Enoximone 50
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 50 mg, 100 mg, or 150 mg, given 3 times daily
Study: 30285645
Drug: Home-based physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based physiotherapy (60 min, twice a week for 12 months)
Study: 24033362
Drug: Control (Amalgam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Amalgam treatment)
Study: 24033362
Drug: Greater treatment
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater treatment levels
Study: 23168823
Drug: Citicoline (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (2000 mg daily for 90 days)
Study: 15919846
Drug: TM-CD care
Approvals — FDA: no, EMA: no, PMDA: no
Description: TM-CD care (n = 329) including AUC elements plus 'stage of change' assessments, mailed workbooks, and monthly calls
Study: 15919846
Drug: Augmented usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented usual care (AUC) (n = 336) including dietary and exercise advice, prescriptions, and dietary recalls
Study: 15016225
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (no needle mounted)
Study: 6542835
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (4.0 mmol h‐1 kg‐1 b. wht.)
Study: 25496674
Drug: Topical lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lignocaine (7 puffs of 10% aerosol)
Study: 25496674
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine (1.5 mg/kg)
Study: 25496674
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline (5 ml of 0.9% saline)
Study: 11865969
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (110, 220, 330, or 440 microg bid)
Study: 10036950
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bid + Amoxicillin 500 mg qid + Clarithromycin 400 mg bid (OAC)
Study: 10036950
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bid + Clarithromycin 400 mg bid (OC)
Study: 2183719
Drug: Cefixime (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (800 mg oral dose)
Study: 2183719
Drug: Amoxicillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (3 g) plus Probenecid (1 g)
Study: 6601746
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg . kg‐1 lidoflazine intravenously before cardiopulmonary bypass (CPB)
Study: 6601746
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg . kg‐1 lidoflazine intravenously before cardiopulmonary bypass (CPB)
Study: 22055480
Drug: Daily multivitamin‐mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin‐mineral supplement
Study: 10340839
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for isolated systolic hypertension; specific intervention details not provided.
Study: 11324827
Drug: reverse transcriptase
Normalized name: Reverse transcriptase
Approvals — FDA: no, EMA: no, PMDA: no
Description: reverse transcriptase inhibitors (zidovudine or didanosine monotherapy or alternating zidovudine and didanosine)
Study: 7153153
Drug: Atropine 0.25
Normalized name: atropine 0.25 mg/0.3 mL intramuscular solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.25 mg
Study: 7153153
Drug: Atropine 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 3.0 mg
Study: 7153153
Drug: Atropine 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 6.0 mg
Study: 30238444
Drug: Deferred endovenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred endovenous ablation of superficial venous reflux, with compression therapy alone
Study: 24503784
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg once daily for ≈4 weeks)
Study: 24503784
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral hypoglycemic agents)
Study: 17575561
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Tramadol Contramid OAD tablet
Study: 17575561
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Tramadol Contramid OAD tablet
Study: 17575561
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Tramadol Contramid OAD tablet
Study: 15694088
Drug: Intramuscular 15‐methyl‐prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 15‐methyl‐prostaglandin F2alpha (125 microg)
Study: 10532693
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment with high doses of lovastatin (40-80 mg/day)
Study: 10532693
Drug: Moderate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate treatment with low doses of lovastatin (2.5-5 mg/day)
Study: 7766739
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily for 4 weeks
Study: 7766739
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg after 8 weeks
Study: 7766739
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg after 8 weeks
Study: 7766739
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg after 2 weeks for patients with ulcer pain
Study: 7766739
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg after 2 weeks for patients with ulcer pain
Study: 7766739
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg after 4 weeks for patients with ulcer pain
Study: 7766739
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg after 4 weeks for patients with ulcer pain
Study: 31289056
Drug: Positive Adjustment
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Adjustment Coping Intervention (PACI) - daily text messages with positive-adjustment coping attitudes
Study: 31289056
Drug: Cognitive distractions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive distractions - daily text messages with cognitive distractions
Study: 22218098
Drug: Active blood
Normalized name: Accu-Chek Active Blood Glucose Meter Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active blood pressure lowering treatment (indapamide SR 1.5 mg plus perindopril 2-4 mg if required)
Study: 16869334
Drug: Pharmacological comfort
Normalized name: Comfort Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological comfort treatments
Study: 16869334
Drug: Nonpharmacological comfort
Normalized name: Comfort Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacological comfort treatments
Study: 10636264
Drug: Dipyridamole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (15 mg in 30 min, stopped 5 min before testing)
Study: 8811376
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral intake (Group I) allowed ab libitum intake of clear liquids starting the first evening after the operation, progressing to a regular diet on the first postoperative day.
Study: 8811376
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral intake (Group I)
Study: 2865518
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mefloquine and sulfadoxine/pyrimethamine
Study: 29859849
Drug: D-amp 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amp 0.3 mg/kg
Study: 27572344
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (15 sessions, daily 30 min)
Study: 27572344
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy (same amount as experimental group)
Study: 23011680
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prednisone daily with methotrexate-based tight control strategy
Study: 16365721
Drug: Oily calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily calcium hydroxide suspension (OCHS) with access flap surgery (AFS)
Study: 17915977
Drug: Lamotrigine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (200 mg/day)
Study: 11134101
Drug: OGTT+F (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: OGTT+F (75 g glucose + 7.5 g fructose)
Study: 11134101
Drug: OGTT‐F (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: OGTT‐F (75 g glucose without fructose)
Study: 8277075
Drug: Nitroglycerin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin plus N-acetylcysteine (0.1 microgram/kg per min + 2 g intravenously, followed by 5 mg/kg per h)
Study: 2929629
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg PPA
Study: 2929629
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg PPA plus 400 mg caffeine
Study: 2929629
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg PPA
Study: 29703040
Drug: Electro-acupuncture (EA)
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture (EA) at ST36-ST37, 20 minutes twice a day for 5 days
Study: 29703040
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies (control group)
Study: 28396238
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose low molecular weight heparin (LMWH) combined with graduated compression stockings (GCS)
Study: 28396238
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose low molecular weight heparin (LMWH) alone
Study: 22033572
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (Beconase(®)), 200 μg daily
Study: 22033572
Drug: Placebo (FESS(®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (FESS(®) saline nasal spray)
Study: 15918622
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting octreotide (100 mcg subcutaneously thrice daily for two weeks, then 20 mg intramuscularly monthly)
Study: 15918622
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 patients who refused treatment)
Study: 12558577
Drug: Sulthiame (STM)
Normalized name: Sulthiame
DrugBank: Sulthiame (DB08329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulthiame (STM) monotherapy
Study: 8383150
Drug: Bacteriostatic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteriostatic saline solution with 1% lidocaine with epinephrine 1:300,000
Study: 8383150
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine with epinephrine 1:100,000 with sodium bicarbonate 80 meq/mL
Study: 8383150
Drug: Bacteriostatic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteriostatic saline solution with 1% lidocaine with epinephrine 1:100,000
Study: 3017392
Drug: Sodium bicarbonate,
Normalized name: Sodium Bicarbonate, 325 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium bicarbonate, 2 g, administered 6 hourly for three doses daily beginning 1 day before DEC was started and continued throughout the DEC therapy.
Study: 3017392
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bicarbonate treatment).
Study: 29773717
Drug: PD-1 inhibitors
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitors (nivolumab)
Study: 23238355
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg racemic ibuprofen suppository
Study: 23238355
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen syrup
Study: 20479446
Drug: 870- and
Normalized name: choline
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 870- and 930-nm light exposure treatment
Study: 16323028
Drug: Lipid-based nasal
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nasal ointment
Study: 16323028
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-use of the test agent)
Study: 8600199
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for symptomatic bacteriuria
Study: 8600199
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment or placebo (Control)
Study: 8358504
Drug: THA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: THA treatment
Study: 29551430
Drug: GnRHa plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa plus add-back (Leuprolide depot 11.25 mg intramuscular injection every 3 months, plus oral norethindrone acetate 5 mg daily)
Study: 29551430
Drug: GnRHa plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa plus modified 2-drug add-back regimen (oral norethindrone acetate 5 mg daily and oral conjugated equine estrogens 0.625 mg daily)
Study: 29282929
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip group (group A)
Study: 29282929
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application group (group B)
Study: 20875374
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR 150 mg
Study: 18550935
Drug: Valsartan/HCTZ (160/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/HCTZ (160/12.5 mg)
Study: 18550935
Drug: HCTZ (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ (25 mg)